Orphan oncology focus Ascelia Pharma concentrates on rare cancer indications with Orviglance and Oncoral, creating dedicated partnerships with niche oncology clinics, radiology centers, and academic hospitals to accelerate access and adoption of orphan-designated therapies.

Orviglance market entry Orviglance is in Phase 3 for detecting focal liver lesions in patients with reduced kidney function, backed by FDA Orphan Drug Designation. This presents a compelling case for collaboration with radiology and hepatology networks seeking improved MR imaging and patient safety.

Oncoral development Oncoral offers an oral irinotecan approach with potential safety and convenience advantages over IV infusions, targeting gastric cancer. This creates sales opportunities with oncology centers favoring outpatient regimens and later-line gastric cancer programs.

Strategic financings Recent funding activity and leadership changes signal ongoing growth and governance readiness for partnerships, licensing, or co-development deals with strategic investors and pharma allies looking to bolster orphan/rare cancer portfolios.

Global exposure Headquartered in Sweden with Nasdaq Stockholm listing and upcoming phase milestones provide visibility to European and global BD teams, offering collaboration prospects with European hospitals, radiology networks, and potential US/EU licensing discussions.